The DOI matches its Crossref record; 195 of the 201 references it cites were found in a registry or an index.
Genes associated with Alzheimer's disease: an overview and current status
Open accessAbstract
Alzheimer's disease (AD) is a progressive, neurodegenerative disease and the most common form of dementia in elderly people. It is an emerging public health problem that poses a huge societal burden. Linkage analysis was the first milestone in unraveling the mutations in APP, PSEN1, and PSEN2 that cause early-onset AD, followed by the discovery of apolipoprotein E-ε4 allele as the only one genetic risk factor for late-onset AD. Genome-wide association studies have revolutionized genetic research and have identified over 20 genetic loci associated with late-onset AD. Recently, next-generation sequencing technologies have enabled the identification of rare disease variants, including unmasking small mutations with intermediate risk of AD in PLD3, TREM2, UNC5C, AKAP9, and ADAM10. This review provides an overview of the genetic basis of AD and the relationship between these risk genes and the neuropathologic features of AD. An understanding of genetic mechanisms underlying AD pathogenesis and the potentially implicated pathways will lead to the development of novel treatment for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It takes 10–20 years for AD to manifest itself (e.g., [5, 69]).”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Research works printed but not linked: 1
- [113]Rajagopalan P Hibar DP Thompson PM TREM2 and neurodegenerative disease N Engl J Med 2013 369 16 1565 1567 24131186 PMC4024453
Cited by
Sorted by citations
Alzheimer’s disease: risk factors and potentially protective measures
Silva, M. V. F., Loures, C. D. M. G., Alves, L. C. V., de Souza, L. C., Borges, K. B. G., & Ferriani, M. D. G. C. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0524-y · Cited by 1,031
Role of gut-brain axis, gut microbial composition, and probiotic intervention in Alzheimer's disease
Kesika, P., Suganthy, N., Sivamaruthi, B. S., & Chaiyasut, C. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118627 · Cited by 479
Lipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
New Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 362
Cellular Specificity of NF-κB Function in the Nervous System
Dresselhaus, E. C., & Meffert, M. K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01043 · Cited by 345
Kwart, D., Gregg, A., Scheckel, C., Murphy, E. A., Paquet, D., Duffield, M. D., Fak, J. J., Olsen, O., Darnell, R. B., & Tessier‐Lavigne, M. (2019) · Neuron · doi:10.1016/j.neuron.2019.07.010 · Cited by 327
In vitro Models of Neurodegenerative Diseases
Slanzi, A., Iannoto, G., Rossi, B., Zenaro, E., & Constantin, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00328 · Cited by 315
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L. R., Daley, D. A., Black, K. L., & Koronyo‐Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 292
Alzheimer’s Amyloid-β is an Antimicrobial Peptide: A Review of the Evidence
Gosztyla, M. L., Brothers, H. M., & Robinson, S. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171133 · Cited by 245
Rossini, P. M., Iorio, R. D., Vecchio, F., Anfossi, M., Babiloni, C., Bozzali, M., Bruni, A. C., Cappa, S. F., Escudero, J., Fraga, F. J., et al. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2020.03.003 · Cited by 257
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Safiri, S., Jolfayi, A. G., Fazlollahi, A., Morsali, S., Sarkesh, A., Sorkhabi, A. D., Golabi, B., Aletaha, R., Asghari, K. M., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 273
Neuroinflammation: A Potential Risk for Dementia
Ahmad, M. A., Kareem, O., Khushtar, M., Akbar, M., Haque, M. R., Iqubal, A., Haider, M. F., Pottoo, F. H., Abdulla, F. S., Al-Haidar, M. B., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020616 · Cited by 174
Inflammasomes, hormesis, and antioxidants in neuroinflammation: Role of NRLP3 in Alzheimer disease
Pennisi, M., Crupi, R., Di Paola, R., Ontario, M. L., Bella, R., Calabrese, E. J., Crea, R., Cuzzocrea, S., & Calabrese, V. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23986 · Cited by 157
Melatonin: A review of its potential functions and effects on neurological diseases
Günata, M., Parlakpınar, H., & Acet, A. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.07.025 · Cited by 158
Neurodegeneration and the Circadian Clock
Hood, S., & Amir, S. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00170 · Cited by 152
Tewari, D., Stankiewicz, A. M., Mocan, A., Sah, A. N., Tzvetkov, N. T., Huminiecki, Ł., Horbańczuk, J. O., & Atanasov, A. G. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00003 · Cited by 142
β-Amyloid and the Pathomechanisms of Alzheimer’s Disease: A Comprehensive View
Penke, B., Bogár, F., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22101692 · Cited by 150
Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation
Gamage, R. V., Wagnon, I. M., Rossetti, I., Childs, R., Niedermayer, G., Chesworth, R., & Gyengési, E. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.577912 · Cited by 134
Alzheimer's disease in the omics era
Sancesario, G. M., & Bernardini, S. (2018) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2018.06.011 · Cited by 113
Robert, J., Button, E. B., Yuen, B., Gilmour, M., Kang, K., Bahrabadi, A., Stukas, S. K., Zhao, W., Kulić, I., & Wellington, C. L. (2017) · eLife · doi:10.7554/elife.29595 · Cited by 118
Role of miRNAs in Alzheimer’s Disease and Possible Fields of Application
Silvestro, S., Bramanti, P., & Mazzon, E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163979 · Cited by 113
Kumar, A., Su, Y., Sharma, M., Singh, S., Kim, S., Peavey, J. J., Suerken, C. K., Lockhart, S. N., Whitlow, C. T., Craft, S., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13055 · Cited by 113
Hoogmartens, J., Cacace, R., & Broeckhoven, C. V. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12155 · Cited by 109
López‐Ortiz, S., Pinto-Fraga, J., Valenzuela, P. L., Martín-Hernández, J., Seisdedos, M. M., García, Ó., Toschi, N., Giuliano, F. D., Garaci, F. G., Mercuri, N. B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062897 · Cited by 107
Golgi Fragmentation in Neurodegenerative Diseases: Is There a Common Cause?
Martínez‐Menárguez, J. A., Tomás, M., Martínez-Martínez, N., & Martínez‐Alonso, E. (2019) · Cells · doi:10.3390/cells8070748 · Cited by 95
Taylor, X., Cisternas, P., You, Y., You, Y., Xiang, S., Marambio, Y. G., Zhang, J., Vidal, R., & Lasagna‐Reeves, C. A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01900-7 · Cited by 93
Vecchio, F., Miraglia, F., Iberite, F., Lacidogna, G., Guglielmi, V., Marra, C., Pasqualetti, P., Tiziano, F. D., & Rossini, P. M. (2018) · Annals of Neurology · doi:10.1002/ana.25289 · Cited by 89
Essential Oils as Treatment Strategy for Alzheimerʼs Disease: Current and Future Perspectives
Benny, A., & Thomas, J. (2018) · Planta Medica · doi:10.1055/a-0758-0188 · Cited by 89
Kim, D. K., Han, D., Park, J., Choi, H., Park, J., Cha, M.-Y., Woo, J. J., Byun, M. S., Lee, D. Y., Kim, Y., et al. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0326-z · Cited by 87
Bioavailability and Pharmaco-therapeutic Potential of Luteolin in Overcoming Alzheimer’s Disease
Ali, F. R., & Siddique, Y. H. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190319141835 · Cited by 82
Ratan, Y., Rajput, A., Maleysm, S., Pareek, A., Jain, V. K., Pareek, A., Kaur, R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11051398 · Cited by 89
Alzheimer’s Disease: Pathogenesis and Therapeutic Interventions
Ogbodo, J. O., Agbo, C. P., Njoku, U. O., Ogugofor, M. O., Egba, S. I., Ihim, S. A., Echezona, A. C., Brendan, K. C., Upaganlawar, A. B., & Upasani, C. D. (2021) · Current Aging Science · doi:10.2174/1874609814666210302085232 · Cited by 86
Fan, J., Tao, W., Li, X., Li, H., Zhang, J., Wei, D., Chen, Y., & Zhang, Z. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051177 · Cited by 87
An overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 89
Friedberg, J. S., Aytan, N., Cherry, J. D., Xia, W., Standring, O. J., Alvarez, V. E., Nicks, R., Svirsky, S. E., Meng, G., Jun, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59869-5 · Cited by 82
Kasza, Á., Penke, B., Frank, Z., Bozsó, Z., Szegedi, V., Hunya, Á. G., Németh, K., Kozma, G., & Fülöp, L. (2017) · Molecules · doi:10.3390/molecules22112007 · Cited by 78
Transcriptomics in Alzheimer’s Disease: Aspects and Challenges
Bagyinszky, E., Giau, V. V., & An, S. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103517 · Cited by 75
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
Treatment strategies in Alzheimer’s disease: a review with focus on selenium supplementation
Aaseth, J., Alexander, J., Bjørklund, G., Hestad, K. A., Dušek, P., Roos, P. M., & Alehagen, U. (2016) · BioMetals · doi:10.1007/s10534-016-9959-8 · Cited by 75
Vassileff, N., Cheng, L., & Hill, A. F. (2020) · Journal of Cell Science · doi:10.1242/jcs.243139 · Cited by 73
Chachaj, A., Gąsiorowski, K., Szuba, A., Sieradzki, A., & Leszek, J. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220411091332 · Cited by 73
Epigenetic Modifications in Alzheimer’s Neuropathology and Therapeutics
Esposito, M. M., & Sherr, G. L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00476 · Cited by 69
Quantile regression for functional partially linear model in ultra-high dimensions
Ma, H., Li, T., Hongtu Zhu, B., & Zhu, Z. (2018) · Computational Statistics & Data Analysis · doi:10.1016/j.csda.2018.06.005 · Cited by 63
Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4
Masuoka, N., Yoshimine, C., Hori, M., Tanaka, M., Asada, T., Abe, K., & Hisatsune, T. (2019) · Nutrients · doi:10.3390/nu11071626 · Cited by 63
Sialometabolism in Brain Health and Alzheimer’s Disease
Rawal, P., & Zhao, L. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.648617 · Cited by 64
Recent Progress in the Pharmacotherapy of Alzheimer’s Disease
Khoury, R., Patel, K., Gold, J., Hinds, S., & Grossberg, G. T. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0499-x · Cited by 62
AbuelEzz, N. Z., Nasr, F. E., Abdulkader, M. A., Bassiouny, A. R., & Zaky, A. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.743573 · Cited by 61
Gao, H., Zhang, A., Yu, J., Sun, H. J., Kong, L. D., Wang, X., Yan, G., Liu, L., & Wang, X. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.06.032 · Cited by 56
INPP5D deficiency attenuates amyloid pathology in a mouse model of Alzheimer's disease
Lin, P. B., Tsai, A. P., Soni, D., Lee‐Gosselin, A., Moutinho, M., Puntambekar, S. S., Landreth, G. E., Lamb, B. T., & Oblak, A. L. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12849 · Cited by 54
Alzheimer’s Disease: A Molecular View of β-Amyloid Induced Morbific Events
Asik, R. M., Suganthy, N., Aarifa, M. A., Kumar, A., Szigeti, K., Máthé, D., Gulyás, B. Z., Archunan, G., & Padmanabhan, P. (2021) · Biomedicines · doi:10.3390/biomedicines9091126 · Cited by 54
Mirabnahrazam, G., Initiative, T. A. D. N., Ma, D., Lee, S., Popuri, K., Lee, H., Cao, J., Wang, L., Galvin, J. E., & Beg, M. F. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220021 · Cited by 50
Rossini, P. M., Miraglia, F., Alù, F., Cotelli, M., Ferreri, F., Iorio, R. D., Iodice, F., & Vecchio, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10020034 · Cited by 49
Genetic Data: Potential Uses and Misuses in Marketing
Daviet, R., Nave, G., & Wind, J. Y. (2020) · Journal of Marketing · doi:10.1177/0022242920980767 · Cited by 59
Diabetes: Risk factor and translational therapeutic implications for Alzheimer's disease
Cummings, J. L., Ortiz, A. A., Castellino, J., & Kinney, J. W. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15619 · Cited by 54
Pontifex, M. G., Martinsen, A., Saleh, R. N. M., Harden, G., Tejera, N., Müller, M. M., Fox, C., Vauzour, D., & Minihane, A. M. (2021) · The FASEB Journal · doi:10.1096/fj.202002621rr · Cited by 51
Bavarsad, N. H., Bagheri, S., Kourosh‐Arami, M., & Komaki, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18492 · Cited by 63
Padhy, B., Hayat, B., Nanda, G. G., Mohanty, P. P., & Alone, D. P. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx329 · Cited by 49
Cerasuolo, M., Di Meo, I., Auriemma, M. C., Paolisso, G., Papa, M., & Rizzo, M. R. (2024) · Biomolecules · doi:10.3390/biom14111362 · Cited by 47
Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease
Chaudhury, S., Patel, T., Barber, I., Guetta‐Baranes, T., Brookes, K. J., Chappell, S., Turton, J. C., Guerreiro, R. J., Brás, J., Hernandez, D. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.035 · Cited by 49
Sen, T., & Thummer, R. P. (2022) · Neurotoxicity Research · doi:10.1007/s12640-022-00564-w · Cited by 52
Flavonoid-Based Nanomedicines in Alzheimer’s Disease Therapeutics: Promises Made, a Long Way To Go
Prasanna, P., & Upadhyay, A. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00224 · Cited by 48
Systems healthcare: a holistic paradigm for tomorrow
Fiandaca, M. S., Mapstone, M. E., Connors, E. E., Jacobson, M., Monuki, E. S., Malik, S., Macciardi, F. M., & Federoff, H. J. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0521-2 · Cited by 49
Pons, V., Lévesque, P., Plante, M.-M., & Rivest, S. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00747-7 · Cited by 46
Pathogenesis of Neurodegenerative Diseases and the Protective Role of Natural Bioactive Components
Samanta, S., Chakraborty, S., & Bagchi, D. (2023) · Journal of the American Nutrition Association · doi:10.1080/27697061.2023.2203235 · Cited by 43
siRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Sajid, M. I., Sheikh, F. S., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Tiwari, R. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114968 · Cited by 50
Ding, Q., Tanigawa, K., Kaneko, J., Totsuka, M., Katakura, Y., Imabayashi, E., Matsuda, H., & Hisatsune, T. (2018) · Aging and Disease · doi:10.14336/ad.2017.0809 · Cited by 43
Alzobaidi, N., Quasimi, H., Emad, N. A., Alhalmi, A., & Naqvi, M. (2021) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s299589 · Cited by 48
Regulation of the Late Onset alzheimer’s Disease Associated HLA-DQA1/DRB1 Expression
Zhang, X., Zou, M., Wu, Y., Jiang, D., Wu, T., Zhao, Y., Wu, D., Cui, J., & Li, G. (2022) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175221085066 · Cited by 45
Fairless, R., Bading, H., & Diem, R. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.741280 · Cited by 45
The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
Cisternas, P., Taylor, X., & Lasagna‐Reeves, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246319 · Cited by 42
Firdaus, Z., & Li, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042320 · Cited by 46
Vlontzou, M. E., Αθανασίου, Μ., Dalakleidi, K. V., Skampardoni, I., Davatzikos, C. A., & Nikita, K. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-92577-6 · Cited by 43
Prasanth, M. I., Malar, D. S., Tencomnao, T., & Brimson, J. M. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1939681 · Cited by 40
Factors Associated with Alzheimer's Disease: An Overview of Reviews
Rochoy, M., Rivas, V., Chazard, E., Decarpentry, E., Saudemont, G., Hazard, P.-A., Puisieux, F. L., Gautier, S., & Bordet, R. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.7 · Cited by 38
Amyloid β induces interneuron-specific changes in the hippocampus of APPNL-F mice
Sos, K. E., Mayer, M. I., Takács, V. T., Major, A., Bardóczi, Z., Beres, B. M., Szeles, T., Saito, T., Saido, T. C., Mody, I., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0233700 · Cited by 37
The dialog between neurons and microglia in Alzheimer's disease: The neurotransmitters view
Stolero, N., & Frenkel, D. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15262 · Cited by 37
Tau Abnormalities and the Potential Therapy in Alzheimer’s Disease
Almansoub, H. A. M. M., Tang, H. R., Wu, Y., Wang, D., Mahaman, Y. A. R., Wei, N., Almansob, Y. A. M., He, W., & Liu, D. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180868 · Cited by 39
Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
Silvestro, S., Valeri, A., & Mazzon, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042011 · Cited by 37
Qin, X., Xiang, Y., Liu, Y., Chen, Y., He, Q., Chen, T., Tang, L., He, B., & Li, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1468561 · Cited by 35
Bridging Genomics to Phenomics at Atomic Resolution through Variation Spatial Profiling
Wang, C., & Balch, W. E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.059 · Cited by 36
The vexing complexity of the amyloidogenic pathway
Castro, M., Hadziselimovic, A., & Sanders, C. R. (2019) · Protein Science · doi:10.1002/pro.3606 · Cited by 40
Schweickart, A., Batra, R., Neth, B. J., Martino, C., Shenhav, L., Zhang, A. R., Shi, P., Karu, N., Huynh, K., Meikle, P. J., et al. (2024) · npj Metabolic Health and Disease · doi:10.1038/s44324-024-00016-3 · Cited by 36
Alterations of Golgi organization in Alzheimer’s disease: A cause or a consequence?
Ayala, I., & Colanzi, A. (2016) · Tissue and Cell · doi:10.1016/j.tice.2016.11.007 · Cited by 34
Genetic Variants and Oxidative Stress in Alzheimer’s Disease
Kowalska, M., Wize, K., Prendecki, M., Lianeri, M., Kozubski, W. P., & Dorszewska, J. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666200224121447 · Cited by 34
γ-secretase promotes Drosophila postsynaptic development through the cleavage of a Wnt receptor
Restrepo, L. J., DePew, A. T., Moese, E. R., Tymanskyj, S. R., Parisi, M. J., Aimino, M. A., Duhart, J. C., Fei, H., & Mosca, T. J. (2022) · Developmental Cell · doi:10.1016/j.devcel.2022.05.006 · Cited by 29
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.027 · Cited by 32
Guest, F. L., Rahmoune, H., & Guest, P. C. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-42667-5_8 · Cited by 34
Kezhu, W., Xu, P., Lü, C., Liming, D., Beiyue, Z., Jingwei, L., Yanyan, Y., & Liu, X. (2016) · Phytotherapy Research · doi:10.1002/ptr.5733 · Cited by 32
Tafoya, M., Madi, S., & Sillerud, L. O. (2016) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25563 · Cited by 32
Reale, M., Gonzales-Portillo, I., & Borlongan, C. V. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146535 · Cited by 33
A concise review of human brain methylome during aging and neurodegenerative diseases
Prasad G, R., & Jho, E.-H. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.10.215 · Cited by 31
Pregnancy as a model for aging
Giller, A., Andrawus, M., Gutman, D., & Atzmon, G. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101093 · Cited by 33
Olsen, I., & Singhrao, S. K. (2020) · Journal of Oral Microbiology · doi:10.1080/20002297.2020.1820834 · Cited by 34
Molecular Pathogenesis and Interventional Strategies for Alzheimer’s Disease: Promises and Pitfalls
Bhute, S., Sarmah, D., Datta, A., Rane, P., Shard, A., Goswami, A., Borah, A., Kalia, K., Dave, K. R., & Bhattacharya, P. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00104 · Cited by 32
Osteoporosis and Alzheimer´s disease (or Alzheimer´s disease and Osteoporosis)
Wanionok, N. E., Morel, G. R., & Fernández, J. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102408 · Cited by 31
Khan, M. S., Qureshi, N., Khan, R., Son, Y., & Maqbool, T. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1578138 · Cited by 37
Hsieh, P., Wang, C., Tsai, C., Yeh, Y., Lee, Y. S., & Wu, Y. (2019) · Brain and Behavior · doi:10.1002/brb3.1281 · Cited by 30
Rao, C. V., Farooqui, M., Madhavaram, A., Zhang, Y., Asch, A. S., & Yamada, H. Y. (2020) · Aging Cell · doi:10.1111/acel.13221 · Cited by 29
Pierouli, K., Papakonstantinou, E., Papageorgiou, L., Diakou, I., Mitsis, Τ., Dragoumani, K., Spandidos, D. A., Bacopoulou, F., Chrousos, G. P., Goulielmos, G. N., et al. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5208 · Cited by 29
Metadata
- Authors
- Giri, M., Lü, Y., & Zhang, M.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 11
- Pages
- 665
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC4876682
- OpenAlex
- W2405825843
- Cited by
- 311
- References
- 201
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 33 · 2023: 33 · 2022: 41 · 2021: 36 · 2020: 41 · 2019: 35 · 2018: 29 · 2017: 21 · 2016: 7
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, genetic risk factors, APP, presenilin 1, presenilin 2, APOE ε4, late-onset Alzheimer's disease, early-onset Alzheimer's disease, genome-wide association study, rare variants, PLD3, TREM2, UNC5C, AKAP9, ADAM10, neuropathology, pathogenesis
- MeSH terms
- Alzheimer Disease, Humans, Mutation, Risk Factors, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Apolipoprotein E4, Presenilin-1, Presenilin-2, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
